464 related articles for article (PubMed ID: 30474852)
1. Does seminal vesicle-sparing robotic radical prostatectomy influence postoperative prostate-specific antigen measured with an ultrasensitive immunoassay?
Burkhardt O; Neuenschwander JE; John H; Randazzo M
Swiss Med Wkly; 2018 Nov; 148():w14685. PubMed ID: 30474852
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
3. The effect of seminal vesicle-sparing radical prostatectomy on serum prostate-specific antigen level.
John H; Hauri D; Maake C
BJU Int; 2003 Dec; 92(9):920-3. PubMed ID: 14632847
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
6. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.
Salomon L; Anastasiadis AG; Johnson CW; McKiernan JM; Goluboff ET; Abbou CC; Olsson CA; Benson MC
Urology; 2003 Aug; 62(2):304-9. PubMed ID: 12893340
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
9. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
10. Ultrasensitive prostate specific antigen assay following laparoscopic radical prostatectomy--an outcome measure for defining the learning curve.
Viney R; Gommersall L; Zeif J; Hayne D; Shah ZH; Doherty A
Ann R Coll Surg Engl; 2009 Jul; 91(5):399-403. PubMed ID: 19409146
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
[TBL] [Abstract][Full Text] [Related]
13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
14. Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision.
Theodorescu D; Lippert MC; Broder SR; Boyd JC
Urology; 1998 Feb; 51(2):277-82. PubMed ID: 9495711
[TBL] [Abstract][Full Text] [Related]
15. The impact of single positive surgical margin features on biochemical recurrence after robotic radical prostatectomy.
Evren I; Hacıislamoğlu A; Ekşi M; Yavuzsan AH; Baytekin F; Çolakoğlu Y; Canoğlu D; Tugcu V
Int Braz J Urol; 2019; 45(1):45-53. PubMed ID: 30325603
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.
Algarra R; Barba J; Merino I; Tienza A; Tolosa E; Robles JE; Zudaire J
Actas Urol Esp; 2015 Apr; 39(3):144-53. PubMed ID: 24996780
[TBL] [Abstract][Full Text] [Related]
17. Does bilateral seminal vesicle invasion at radical prostatectomy predict worse prognosis than unilateral invasion among patients with pT3b prostate cancers?
Lee HJ; Han JH; Lee DH; Nam JK; Kim TN; Chung MK; Park SW
Int J Urol; 2016 Sep; 23(9):758-63. PubMed ID: 27305865
[TBL] [Abstract][Full Text] [Related]
18. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
19. Preoperative prostate specific antigen and prostate volume are significant predictors of seminal vesicle invasion in patients with prostate cancer.
Sfoungaristos S; Perimenis P
Prague Med Rep; 2011; 112(4):263-71. PubMed ID: 22142521
[TBL] [Abstract][Full Text] [Related]
20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
